Effectiveness of Varicella Zoster Immune Globulin Administration within 96 Hours versus more than 96 Hours after Exposure to the Varicella-Zoster Virus
0
조회
0
다운로드
0
인용
0
참고문헌
키워드
초록
Purpose: Varicella Zoster Immune Globulin (VZIG) is available in Korea for post-exposure prophylaxis of the Varicella-zoster virus (VZV) in high-risk patients. In July 2013, the United States Centers for Disease Control and Prevention (US CDC) recommended extending the time for administration of VariZIG® from within 96 hours up to 10 days after VZV exposure. This study was performed to analyze the effectiveness of VZIG prophylaxis between the two groups of patients who received VZIG within 96 hours and more than 96 hours of exposure to varicella. Methods: A retrospective chart review was performed in pediatric patients who received VZIG at Samsung Medical Center, Seoul, Korea from January 2001 to December 2012. Results: A total of 91 patients were identified. Fifty-seven patients were male (62.6%) and the median age was 5.91 years. Thirty-nine patients (42.9%) were exposed to VZV in the hospital. Underlying diseases were solid tumors (41.8%), hematologic malignancies (40.7%), and others (17.5%). Forty-five patients (49.5%) were hematopoietic cell transplant recipients. Seventy-four patients (81.3%) received VZIG within 96 hours after VZV exposure. There was no significant difference in the development of chickenpox between the two groups (2.7% vs. 5.9%, P =0.4664). In 22 seronegative patients, we also observed no significant difference between the groups in terms of the development of chickenpox (6.6% vs. 0%, P =0.667). Conclusions: This study showed that the effectiveness of VZIG for the prevention of chickenpox was comparable between patients who received VZIG within 96 hours and those who received VZIG more than 96 hours after exposure to VZV.
Abstract
Purpose: Varicella Zoster Immune Globulin (VZIG) is available in Korea for post-exposure prophylaxis of the Varicella-zoster virus (VZV) in high-risk patients. In July 2013, the United States Centers for Disease Control and Prevention (US CDC) recommended extending the time for administration of VariZIG® from within 96 hours up to 10 days after VZV exposure. This study was performed to analyze the effectiveness of VZIG prophylaxis between the two groups of patients who received VZIG within 96 hours and more than 96 hours of exposure to varicella. Methods: A retrospective chart review was performed in pediatric patients who received VZIG at Samsung Medical Center, Seoul, Korea from January 2001 to December 2012. Results: A total of 91 patients were identified. Fifty-seven patients were male (62.6%) and the median age was 5.91 years. Thirty-nine patients (42.9%) were exposed to VZV in the hospital. Underlying diseases were solid tumors (41.8%), hematologic malignancies (40.7%), and others (17.5%). Forty-five patients (49.5%) were hematopoietic cell transplant recipients. Seventy-four patients (81.3%) received VZIG within 96 hours after VZV exposure. There was no significant difference in the development of chickenpox between the two groups (2.7% vs. 5.9%, P =0.4664). In 22 seronegative patients, we also observed no significant difference between the groups in terms of the development of chickenpox (6.6% vs. 0%, P =0.667). Conclusions: This study showed that the effectiveness of VZIG for the prevention of chickenpox was comparable between patients who received VZIG within 96 hours and those who received VZIG more than 96 hours after exposure to VZV.
참고문헌 (29)
- "Prevention of varicella. Update recommendations of the Advisory Committee on Immunization Practices (ACIP)", MMWR Recomm Rep, 48, pp.1~5 (1999)
- Feldman S, "Varicella in children with cancer: Seventy-seven cases", Pediatrics, 56, pp.388~397 (1975)
- Levin MJ., "Varicella vaccination of immunocompromised children", J Infect Dis, 197(Suppl 2), pp.S200~S206 (2008)
- Marin M, "Prevention of varicella: recommendations of the Advisory Committee on Immunization Practices (ACIP)", MMWR Recomm Rep, 56, pp.1~40 (2007)
- Orenstein WA, "Prophylaxis of varicella in high-risk children: dose-response effect of zoster immune globulin", J Pediatr, 98, pp.368~373 (1981)
- "Updated recommendations for use of VariZIG--United States, 2013", MMWR Morb Mortal Wkly Rep, 62, pp.574~576 (2013)
- Winsnes R, "Efficacy of zoster immunoglobulin in prophylaxis of varicella in high-risk patients", Acta Paediatr Scand, 67, pp.77~82 (1978)
- Evans EB, "Human anti-chickenpox immunoglobulin in the prevention of chickenpox", Lancet, 1, pp.354~356 (1980)
- Enders G ME, "Varicella and herpes zoster in pregnancy and the newborn" (2000), Cambridge University Press
- Koren G, "Serum concentrations, efficacy, and safety of a new, intravenously administered varicella zoster immune globulin in pregnant women", J Clin Pharmacol, 42, pp.267~274 (2002)
- Pickering LK, "Red book", pp.92~781 (2012)
- Cameron JC, "Severe complications of chickenpox in hospitalised children in the UK and Ireland", Arch Dis Child, 92, pp.1062~1066 (2007)
- Balfour HH, Jr., "Varicella zoster virus infections in immunocompromised hosts. A review of the natural history and management", Am J Med, 85, pp.68~73 (1988)
- Swingler G., "Chickenpox", Clin Evid, pp.755~762 (2003)
- "Prevention of varicella: Recommendations of the Advisory Committee on Immunization Practices (ACIP)", MMWR Recomm Rep, 45, pp.1~36 (1996), Centers for Disease Control and Prevention
- Arvin AM., "Varicella-zoster virus", Clin Microbiol Rev, 9, pp.361~381 (1996)
- Roderick M, "Chickenpox in the immunocompromised child", Arch Dis Child, 97, pp.587~589 (2012)
- Feldman S, "Varicella in children with cancer: impact of antiviral therapy and prophylaxis", Pediatrics, 80, pp.465~472 (1987)
- Brandt L, "A survey of recommendations given to patients going home after bone marrow transplant", Arch Dis Child, 71, pp.529~531 (1994)
- Weinstock DM, "Postexposure prophylaxis against varicella zoster virus infection among hematopoietic stem cell transplant recipients", Biol Blood Marrow Transplant, 12, pp.1096~1097 (2006)
- Bate J, "PEPtalk: postexposure prophylaxis against varicella in children with cancer", Arch Dis Child, 96, pp.841~845 (2011)
- Weinstock DM, "Postexposure prophylaxis against varicella-zoster virus infection among recipients of hematopoietic stem cell transplant: unresolved issues", Infect Control Hosp Epidemiol, 25, pp.603~608 (2004)
- Salzman MB, "Postexposure varicella vaccination in siblings of children with active varicella", Pediatr Infect Dis J, 17, pp.256~257 (1998)
- Brunell PA, "Prevention of varicella by zoster immune globulin", N Engl J Med, 280, pp.1191~1194 (1969)
- Brunell PA, "Prevention of varicella in high risk children: a collaborative study", Pediatrics, 50, pp.718~722 (1972)
- Zaia JA, "Evaluation of varicella-zoster immune globulin:protection of immunosuppressed children after household exposure to varicella", J Infect Dis, 147, pp.737~743 (1983)
- "A new product (VariZIG) for postexposure prophylaxis of varicella available under an investigational new drug application expanded access protocol", MMWR Morb Mortal Wkly Rep, 55, pp.209~210 (2006)
- "FDA approval of an extended period for administering VariZIG for postexposure prophylaxis of varicella", MMWR Morb Mortal Wkly Rep, 61, pp.212~ (2012)
- Enders G, "Consequences of varicella and herpes zoster in pregnancy:prospective study of 1739 cases", The Lancet, 343, pp.1548~1551 (1994)